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Background: Differential diagnosis of high-grade dysplastic nodules (HGDN) and well-differentiated hepatocellular
carcinoma (WDHCC) represents a challenge to experienced hepatic clinicians, radiologists and hepatopathologists.
Methods: The expression profiles of aminoacylase-1 (ACY1), sequestosome-1 (SQSTM1) and glypican-3 (GPC3) in
low-grade dysplastic nodules (LGDN), HGDN and WDHCC were assessed by immunohistochemistry. The differential
diagnostic performances of these three markers alone and in combination for HGDN and WDHCC were
investigated by logistic regression models (HGDN = 21; WDHCC = 32) and validated in an independent test set
(HGDN, n = 21; WDHCC n = 24). Postoperative overall survival and time to recurrence were evaluated by univariate
and multivariate analyses in an independent set of 500 patients.
Results: ACY1, SQSTM1 and GPC3 were differentially expressed in each group. For the differential diagnosis of
WDHCC from HGDN, the sensitivity and specificity of the combination of ACY1 + SQSTM1 + GPC3 for detecting
WDHCC were 93.8% and 95.2% respectively in the training set, which were higher than any of the three two-marker
combinations. The validities of the four diagnostic models were further confirmed in an independent test set, and
corresponding good sensitivity and specificity were observed. Interestingly, GPC3 expression in HCC tissues
combined with serum α-fetoprotein (AFP) was found to be an independent predictor for overall survival and time
to recurrence.
Conclusions: ACY1 + SQSTM1 + GPC3 combination represents a potentially valuable biomarker for distinguishing
between WDHCC and HGDN using immunohistochemistry. Meanwhile, low GPC3 staining combined with positive
serum AFP may play a practical role in predicting poor postoperative outcome and high tumor recurrence risk.
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Hepatocellular carcinoma (HCC) is one of the most
prevalent human cancers worldwide, with 82% of cases
occurring in developing countries, including 55% in
China) [1]. HCC occurs mainly in patients with chronic
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reproduction in any medium, provided the orvirus infection-based liver cirrhosis. Dysplastic nodules
(DN) are pre-cancerous lesions of HCC and high-grade
DN (HGDN) has a high risk of malignant transformation
[2-5]. However, detection of DN, especially HGDN, and
its differentiation from small well-differentiated HCC
(WDHCC) are sometimes very difficult on the basis of
morphologic features alone. Although recent advances
in imaging techniques have increased the frequency of
detection of small lesions, issues such as the low specifi-
city of their identification remain to be resolved [6,7].
It has been reported that HSP70, glypican-3 (GPC3),
glutamine synthetase (GS), CD31, α-smooth muscleThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ential diagnosis of HCC or WDHCC and DN or HGDN
[8-13]. However, the sensitivity of the individual markers
for distinguishing between WDHCC and HGDN were
only 78.1% for HSP70, 59.4% for GS, and 68.8% for GPC3,
respectively [10], and CD34 immunoreactivity may be in-
creased in HGDN [14], which may influence the accuracy
of the pathological diagnosis and subsequent therapy.
There is thus a need to develop new markers for the dif-
ferential diagnosis of HGDN and WDHCC.
Using the iTRAQ-2DLC-ESI-MS/MS technique, we re-
cently identified 147 proteins, including 52 that were up-
regulated and 95 that were down-regulated in small HCC,
and identified aminoacylase-1 (ACY1) and sequestosome-1
(SQSTM1) as candidate immunohistochemical markers for
distinguishing between small HCCs (<3 cm) and DN [15].
To the best of our knowledge, the relationship between
ACY1 and SQSTM1 expression in small HCC and postop-
erative prognosis has not yet been studied, and few studies,
with only small sample sizes, have described the prognostic
role of GPC3 in patients with HCC [16-19].
In the present study, we therefore analyzed the expres-
sion patterns of ACY1, SQSTM1, and GPC3 among
low-grade DN (LGDN), HGDN, WDHCC and moderately
differentiated HCC (MDHCC), and determined the accur-
acies of different panels of markers using ACY1, SQSTM1,
and GPC3. In addition, we established four differential
diagnostic models by logistic regression analyses to evaluate
their diagnostic values for distinguishing small WDHCC
from HGDN, and externally validated the results in an
independent set of 45 samples. We also evaluated the prog-
nostic values of ACY1, SQSTM1 and GPC3, and demon-
strated that GPC3 combined with serum α-fetoprotein
(AFP), and TNM stage were independent prognostic fac-
tors for overall survival (OS) and time to recurrence (TTR).
Methods
Patients and specimens
A total of 129 formalin-fixed paraffin-embedded (FFPE)
tissues from liver nodules (diagnostic group; LGDN = 25,
HGDN= 42, WDHCC= 56, MDHCC= 19) were randomly
selected retrospectively from patients who underwent
curative resection between 2005 and 2011 at the Eastern
Hepatobiliary Surgery Hospital (EHBH), Second Military
Medical University, Shanghai, China (diagnostic group in
Additional file 1: Table S1). An additional cohort of 500
FFPE tissues was randomly selected retrospectively from
HCC patients who underwent curative resection from
January 1996 to September 2001 in the same hospital as
a follow up group (prognostic group in Additional file 1:
Table S1). Complete follow-up data were available for pa-
tients in the prognostic group. Patients were followed until
October 2008, with a median follow-up of 33.0 months
(range, 0.3–141.0 months). Computed tomography and/ormagnetic resonance imaging and an elevated serum AFP
level (>20 ng/ml) were used to verify tumor recurrence in
suspected cases.
Hematoxylin and eosin (HE)-stained slides were made
from each FFPE tissue sample and were reviewed by two
experienced hepatopathologists (WM-Cong and H-Dong).
Diagnoses of LGDN and HGDN were based on the
criteria proposed by the International Consensus Group
for Hepatocellular Neoplasia (ICGHN) and the World
Health Organization (WHO) [20,21]. Briefly, hepatocytes
in LGDN appear normal or show minimal nuclear atypia
and a slightly increased nucleus to cytoplasmic (N:C)
ratio, but mitotic figures are absent. HGDN is characterized
by cytologic and/or structural atypia, but insufficient for a
diagnosis of WDHCC. The cytologic atypia may be diffuse
or focal and is characterized by nuclear hyperchromasia,
nuclear contour irregularities, cytoplasmic basophilia or
clear cell changes, high N:C ratio, and occasional mitotic
figures. Architecturally, the cell plates are thickened up to
three cells, with occasional foci of pseudoglandular forma-
tion. All WDHCC and MDHCC in the diagnostic group
were <3 cm in diameter. WDHCC was diagnosed mainly
based on the following major histologic features proposed
by ICGHN and WHO: (1) increased cell density, more
than twice that of the surrounding liver, with increased N:C
ratio; (2) irregular thin-trabecular pattern of growth; (3)
pseudoglandular structures; (4) fatty change; (5) unpaired
arteries; (6) intratumoral portal tracts; and (7) stromal inva-
sion [20,21]. Tumor stage was defined according to the
2002 American Joint Committee on Cancer/International
Union Against Cancer tumor node metastasis (TNM) clas-
sification system [22].
A total of 642 specimens obtained from 632 patients
were therefore used in the present study. Among these,
142 specimens were included in the diagnostic group
and 500 in the prognostic group. The baseline character-
istics of the patients are summarized in Additional file 1:
Table S1. Approval from the Ethics Committee of EHBH
and written informed consent from each patient were
obtained prior to the use of these clinical materials for
investigation.
Tissue microarrays, immunohistochemistry and scoring
Tissue microarrays were constructed as reported previ-
ously [23], using 597 samples selected randomly from
642 specimens. The remaining 45 specimens, including
21 HGDN and 24 WDHCC specimens were used for the
diagnostic validation set. HE-stained slides from all pa-
tients were reviewed and identified by two experienced
pathologists (WM-Cong. and H-Dong) and the represen-
tative two cores were pre-marked in the paraffin blocks.
Tissue cylinders with a diameter of 2 mm were punched
from the marked areas of each block and incorporated into
a recipient paraffin block. Sections 4-μm thick were placed
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fin sections were deparaffinized in xylene and rehydrated
through decreasing concentrations of ethanol (100%, 95%,
and 85%, 5 min each). Antigens were unmasked by micro-
wave irradiation for 3 min in pH 6.0 citric buffer and
cooled at room temperature for 60 min. Endogenous
peroxidase activity was blocked by incubation of the slides
in 3% H2O2/phosphate-buffered saline, and nonspecific
binding sites were blocked with goat serum. Primary anti-
bodies were diluted as follows: mouse monoclonal anti-
body against ACY1 (ab54960; Abcam, Hong Kong, China;
1:250 dilution, cytoplasmic staining), mouse polyclonal an-
tibody against SQSTM1 (P0067; Sigma-Aldrich, St. Louis,
MO, USA); 1:1000 dilution, cytoplasmic staining), mouse
monoclonal antibody against GPC3 (Clone 1G12; Bio-
Mosaics, USA; 1:200 dilution, cytoplasmic staining).
An EnVision Detection kit (GK500705: Gene Tech,
Shanghai, China) was used to visualize tissue antigens.
Tissue sections were counterstained with hematoxylin
for 5 min. Negative control slides omitting the primary
antibodies were created for all assays. The integrated op-
tical density (IOD) as the positive-staining density was
measured as reported previously [24]. The image system
comprised a Leica CCD camera DFC420 connected to
a Leica DM IRE2 microscope (Leica Microsystems Im-
aging Solutions Ltd, Cambridge, United Kingdom). Pho-
tographs of representative fields were captured under
high-power magnification (×200) using Leica QWin Plus
v3 software. The IODs of all the negative- and positive-
stained regions in each photograph were counted and
measured using Image-Pro Plus v6.0 software (Media
Cybernetics Inc, Bethesda, MD, USA). In addition, cases
were semiquantitatively evaluated by two pathologists
(WM-Cong. and H-Dong) who were blinded to the clini-
copathological data. The intensity of immunostaining
was scored on the basis of the percentage of positive
tumor cells: 0 (−) (0–15%), 1 (+) (16–25%), 2 (++) (26–
50%), and 3 (+++) (>51%) for ACY1 and SQSTM1 and 0
(−) (0–5%), 1 (+) (6–10%), 2 (++) (11–50%), and 3 (+++)
(>51%) for GPC3.
Construction of diagnostic models and validation of
diagnostic efficiency
HGDN (n = 21) and WDHCC (n = 32) scores from im-
munohistochemistry were used to construct diagnostic
models (training data set from tissue microarray). The
scores (0, 1, 2, 3) for ACY1, SQSTM1, and GPC3 were
subjected to logistic regression to generate differential
diagnostic models for the detection of WDHCC. The
output was the diagnostic score in the range of 0–1. Dur-
ing model construction, the diagnostic score for an
HGDN lesion was defined as ‘0’, while that for a WDHCC
lesion was defined as ‘1’. The predictive probability of this
model was applied to the same data set (HGDN= 21,WDHCC= 32), and receiver operator characteristic curve
(ROC) analysis was performed.
The differential diagnostic models were then applied
to classify the HGDN and WDHCC cases in the inde-
pendent validation set (HGDN = 21, WDHCC = 24). The
diagnostic scores, which were computed from the model
using the immunostaining scores for ACY1, SQSTM1,
and GPC3 in individual cases, were used as an index for
classifying the WDHCC and HGDN.Statistical analyses
Statistical analyses were carried out using SPSS 13.0
software (SPSS, Chicago, IL, USA). The relationships be-
tween the expression of biomarkers and hepatocellular
tumors (LGDN, HGDN, WDHCC, and MDHCC) were
analyzed by calculating Spearman’s correlation coeffi-
cient (r). Quantitative variables were analyzed using Stu-
dent’s t-test or the Mann–Whitney test. Experimental
data were presented as the mean of each condition ± S.D.
or S.E.M, and values of p < 0.05 were considered statisti-
cally significant. ROC curves were used to determine the
sensitivity, specificity, and corresponding cut-off value for
each marker or panel of markers [25].
For survival analyses, ACY1, SQSTM1, and GPC3 ex-
pression levels were divided into low and high levels as
follows: ACY1: low (−), high (+, ++); SQSTM1: low (−, +),
high (++, +++); GPC3: low (−, +), high (++, +++). Uni-
variate analysis was performed using the Kaplan-Meier
method (log-rank test). Multivariate analysis was per-
formed using Cox’s multivariate proportional hazards
regression model in a stepwise manner (forward, condi-
tional likelihood ratio).Results
Features of expression profiles
The expression levels of ACY1 in WDHCC and MDHCC
were lower than in LGDN and HGDN. In contrast, the
expression levels of SQSTM1 and GPC3 were higher
in WDHCC and MDHCC than in LGDN and HGDN
(Figure 1A). As shown in Figure 1B, the expression levels
(based on IOD) of ACY1 in WDHCC and MDHCC were
significantly lower than in HGDN, and SQSTM1 and
GPC3 were significantly higher in WDHCC and MDHCC
than in HGDN. The immunoreactivity score distribution
of ACY1 decreased significantly in line with the step-
wise progression of hepatocarcinogenesis (from LGDN
to MDHCC) (Spearman’s r = −0.639, p < 0.0001), whereas
SQSTM1 and GPC3 increased significantly in line with
the same progression (Spearman’s r = 0.644 for SQSTM1;
Spearman’s r = 0.616 for ACY1, p < 0.0001 for both). The
proportion of positive immunoreactivity also showed step-
wise changes; for instance, negative immunoreactivity
for SQSTM1 was demonstrated in 84.0% of LGDN, 81.0%
GPC3





















































Figure 1 Representative HE-stained sections and immunohistochemical staining for ACY1, SQSTM1, and GPC3 (×200). (A) Typical
HE-stained sections and immunostaining for ACY1, SQSTM1, and GPC3 are shown for LGDN, HGDN, WDHCC, and MDHCC. P, positive
immunostaining; N, negative immunostaining. (B) Immunohistochemical expression of ACY1, SQSTM1, and GPC3 in LGDN, HGDN, WDHCC,
and MDHCC. A box and whisker plot (whiskers: 10–90%) of IOD for each marker was obtained from the tissue microarrays. Mann–Whitney tests
showed a significant difference between WDHCC (32 lesions) and MDHCC (19 lesions) compared with HGDN (21 lesions).
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(Table 1).
Significance of diagnostic models
To enhance the diagnostic efficiency, logistic regression
analyses were used to construct four diagnostic models
using the immunohistochemistry scores (HGDN = 21,
WDHCC = 32), and the best cut-off values were deter-
mined by ROC curves. The areas under the curve
(AUC) were 0.857 (95% CI, 0.752–0.962, p < 0.0001) for
ACY1, 0.837 (95% CI, 0.722–0.952, p < 0.0001) for
SQSTM1, and 0.795 (95% CI, 0.676–0.915, p = 0.0003)
for GPC3 (Figure 2). However, the AUCs were 0.935
(95% CI, 0.860–1.009, p < 0.0001, cut-off value = 0.6585)
for ACY1 + SQSTM1 combination, 0.902 (95% CI, 0.815-
0.989, p < 0.0001, cut-off value = 0.5335) for ACY1 +GPC3combination, 0.921 (95% CI, 0.847–0.995, p < 0.0001, cut-
off value = 0.3226) for SQSTM1+GPC3 combination, and
0.943 (95% CI, 0.870–1.016, p < 0.0001, cut-off value =
0.6366) for ACY1+ SQSTM1+GPC3 combination, sug-
gesting that the AUCs for marker combinations were
much higher than those for any individual marker. ACY1 +
SQSTM1+GPC3 combination was better than any two-
marker combination. The resulting diagnostic models are
summarized in Additional file 1: Table S2.
Values of marker combinations
The sensitivity, specificity, and positive and negative pre-
dictive values of the individual markers and four models
for WDHCC detection are summarized in Table 2. Good
sensitivity (84.4%) coupled with good specificity (81.0%)
for WDHCC detection was seen for SQSTM1 alone.
Table 1 Immunoreaction score distribution of ACY1,
SQSTM1, and GPC3 according to histologic grade in LGDN,
HGDN, WDHCC, and MDHCC
ACY1 % SQSTM1 % GPC3 %
25 LGDN - 3 12.0 21 84.0 25 100.0
(n = 25) + 16 64.0 2 8.0 0 0.0
++ 6 24.0 2 8.0 0 0.0
+++ 0 0.0 0 0.0 0 0.0
21 HGDN - 1 4.8 17 81.0 20 95.2
(n = 21) + 14 66.7 2 9.5 1 4.8
++ 6 28.6 2 9.5 0 0.0
+++ 0 0.0 0 0.0 0 0.0
32 WDHCC - 24 75.0 5 15.6 12 37.5
(n = 32) + 6 18.8 12 37.5 11 34.4
++ 2 6.3 11 34.4 5 15.6
+++ 0 0.0 4 12.5 4 12.5
19 MDHCC - 17 89.5 3 15.8 6 31.6
(n = 19) + 2 10.5 3 15.8 3 15.8
++ 0 0.0 3 15.8 7 36.8
+++ 0 0.0 10 52.6 3 15.8
r −0.639 0.644 0.616
p < 0.0001 < 0.0001 < 0.0001
NOTE. LGDN, low grade dysplastic nodule; HGDN, high grade dysplastic
nodule; WDHCC, welldifferentiated hepatocellular carcinoma; MDHCC,
moderately differentiated hepatocellular carcinoma; r, correlation coefficient;
p, spearman correlation (from LGDN to MDHCC).
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GPC3 (positive) for the detection of WHHCC were 75.0%
and 95.2%, and 62.5% and 95.2%, respectively. However,
the sensitivities and specificities for discriminating between
WDHCC and HGDN were 84.4% and 95.2% for ACY1 +
















Figure 2 ROC curve analysis of individual markers and combinations
and HGDN lesions. AUCs were 0.857 for ACY1, 0.837 for SQSTM1, 0.795 fo
SQSTM1 + GPC3, 0.943 for ACY1 + SQSTM1 + GPC3.GPC3 combination, 93.8% and 81.0% for SQSTM1+
GPC3 combination, and 93.8% and 95.2% for ACY1+
SQSTM1+GPC3 combination. Notably, the sensitivity
and specificity for discriminating between WDHCC and
HGDN were significantly improved by combining ACY1 +
SQSTM1+GPC3.
Model evaluation
The four models were evaluated by applying them to the
independent sample set. We tested the expression pro-
files of the three markers (ACY1, SQSTM1, and GPC3)
in a validation set of HGDN (n = 21) and WDHCC (n = 24).
Typical immunostaining of serial large sections of HGDN
and WDHCC is shown in Figure 3. As in tissue microarray
analyses, ACY1 was significantly down-regulated in HCC
compared with HGDN, while SQSTM1 and GPC3 were
significantly up-regulated in HCC compared with HGDN.
The immunostaining scores for ACY1, SQSTM1, and
GPC3 in individual cases were used as indexes for clas-
sifying WDHCC (n = 24) and HGDN (n = 21). Finally,
79.2% of WDHCCs (19/24) and 57.1% of HGDNs (12/21)
were correctly classified by the ACY1 + SQSTM1, 83.3%
of WDHCCs (20/24) and 57.1% of HGDNs (12/21) by
ACY1 +GPC3, 83.3% of WDHCCs (20/24) and 90.5% of
HGDNs (19/21) by SQSTM1+GPC3, and 79.2% of WD
HCCs (19/24) and 95.2% of HGDNs (20/21) by ACY1 +
SQSTM1+GPC3. Notably, the SQSTM1+GPC3 and
ACY1 + SQSTM1+GPC3 combinations demonstrated
high sensitivity and good specificity for discriminating be-
tween WDHCC and HGDN (Additional file 1: Table S3).
Prognostic significance
At the time of the last follow-up, 312 of 500 patients had
tumor recurrence and 279 patients had died, including 34
patients with no record of tumor recurrence. UnivariateSource of the curve
ACY1, AUC=0.857 (95% Cl, 0.752-0.962, p < .0001)
SQSTM1, AUC=0.837 (95% Cl, 0.722-0.952, p < .0001)
GPC3, AUC=0.795 (95% Cl, 0.676-0.915, p =.0003)
ACY1+SQSTM1, AUC=0.935 (95% CI, 0.860-1.009, p < .0001)
ACY1+GPC3, AUC=0.902 (95% CI, 0.815-0.989, p < .0001)
SQSTM1+GPC3, AUC=0.921 (95% CI, 0.847-0.995, p < .0001)
ACY1+SQSTM1+GPC3, AUC=0.943 (95% CI, 0.870-1.016, p< .0001)
of ACY1, SQSTM1, and GPC3 for discriminating between WDHCC
r GPC3, 0.935 for ACY1 + SQSTM1, 0.902 for ACY1 + GPC3, 0.921 for
Table 2 Sensitivity, specificity, positive and negative predictive values for WDHCC detection using individual markers
and marker combinations
WDHCC (n = 32) HGDN (n = 21) Sen Spe PPV NPV
ACY1 negative 24 1 75.0% 95.2% 96.0% 71.4%
SQSTM1 positive 27 4 84.4% 81.0% 87.1% 77.3%
GPC3 positive 20 1 62.5% 95.2% 95.2% 95.2%
Predicted by ACY1 + SQSTM1 27 20 84.4% 95.2% 96.4% 80.0%
Predicted by ACY1 + GPC3 28 13 87.5% 61.9% 77.8% 76.5%
Predicted by SQSTM1 + GPC3 30 17 93.8% 81.0% 88.2% 89.5%
Predicted by ACY1 + SQSTM1 + GPC3 30 20 93.8% 95.2% 96.8% 90.9%
NOTE. LGDN, low grade dysplastic nodule; HGDN, high grade dysplastic nodule; WDHCC, welldifferentiated hepatocellular carcinoma; MDHCC, moderately
differentiated hepatocellular carcinoma; Sen, sensitivity; Spe, specification; PPV, positive predictive value; NPV, negative predictive value.
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OS time for patients with HCC expressing low levels of
GPC3 was 34.3 (95% CI, 25.9–42.7) months, compared
with 72.3 (95% CI, 48.3–99.4) months for patients with
HCC expressing high levels of GPC3 (p = 0.001; log-rank
test; Figure 4A). The median TTR for patients with HCC
expressing low levels of GPC3 was 19.2 (95% CI, 13.1–
25.3) months, compared with 32 (95% CI, 16.9–47.1)
months for patients with HCC expressing high levels
of GPC3 (p = 0.004; log-rank test; Figure 4B). However,
ACY1, and SQSTM1 had no prognostic significance for
OS and TTR (Additional file 1: Figure S1A–D). Further-
more, serum AFP (Figure 4C), TNM stage, tumor differen-
tiation, and vascular invasion (Additional file 1: Figure S1E,
G, I) were also significantly associated with OS, and serum
AFP (Figure 4D), TNM stage, vascular invasion (Additional
file 1: Figure S1F, J) were significantly associated with TTR.
The median OS for patients who were negative for serum
AFP was 72.6 (95% CI, 48.9–96.3) months, compared with
33.3 (95% CI, 24.0–42.6) months for serum AFP-positive
patients (p = 0.005; log-rank test; Figure 4C). The median
OS times for TNM stage, tumor differentiation, and vascu-
lar invasion were: TNM state, I vs II vs III–IV = 72.6 vs 44
vs 13.3 months; tumor differentiation, well vs moderate vs
poor = 80.8 vs 40.4 vs 12.8 months; and vascular invasion,
no vs yes = 72.3 vs 32.3 months. In addition, Kaplan-Meier
analysis showed that sex, age, hepatitis B surface antigen
(HBsAg), cirrhosis, and Child-Pugh class had no prognos-
tic significance for OS and TTR. Tumor differentiation
was not associated TTR.
Interestingly, when GPC3 staining and serum AFP
were considered together, the OS and TTR rates were
significantly better in AFP-negative/GPC3-high patients
compared with AFP-positive/GPC3-low patients, while
AFP-negative/GPC3-low and AFP-positive/GPC3-high pa-
tients showed intermediate OS and TTR rates. Further,
multivariate Cox regression analysis indicated that, as for
TNM stage, GPC3 staining combined with serum AFP
was an independent prognostic factor for postoperative
outcome and tumor recurrence in HCC patients (Table 3).Discussion
Differentiating between HGDN and WDHCC represents
a challenge even to experienced hepatic clinicians, radi-
ologists and hepatopathologists, and the pathological dif-
ferentiation of pre-neoplastic lesions, particularly HGDN
and small WDHCC, is always questionable [20,21,26,27].
Although several immunohistochemical markers such as
GPC3, HSP70, GS, and EZH2 have been reported to play
roles in the diagnosis of HCC, some limitations remain
[10,13,28]; e.g., the sensitivity and specificity of GPC3 for
the diagnosis of small HCC were 77% and 96% respec-
tively in resected cases [29], and 61.4% and 92% respec-
tively in needle biopsies [13]. Based on our experience in
EHBH, the immunohistochemical sensitivity of GPC3 in
3,232 cases of HCC (from August 2010 to July 2011) was
only 63.1%, while those of HSP70 and GS were not as high
as expected (data not shown). Such limitations may result
in confusion between small WDHCC and HGDN.
In the present study, we used ACY1 and SQSTM1,
which were initially identified by screening in our la-
boratory [15], and a ‘star molecule’ GPC3 to establish
diagnostic panels to differentiate between HGDN and
WDHCC using logistic regression analyses. The models
were then further validated in an independent set of
WDHCC and HGDN samples. ACY1, SQSTM1, and
GPC3 expression differed significantly between WDHCC
and HGDN (Additional file 1: Table S4). In addition,
there were no differences in expression levels of ACY1,
SQSTM1 or GPC3 in HCCs <2 cm or 2–3 cm in diam-
eter (Additional file 1: Figure S2).
Moreover, the sensitivity and specificity of ACY1 +
SQSTM1 +GPC3 were higher than those of any single
marker or any two-marker combination, with a sensitiv-
ity and specificity of 93.8% and 95.2%, respectively, for
this new diagnostic model of ACY1 + SQSTM1 + GPC3
combination, constructed by logistic regression. The im-
munostaining scores for ACY1, SQSTM1, and GPC3
can be input into Model 4 during routine daily practice.
The model can be easily set up and processed using a
workstation. An output value ≤0.6366 is considered highly
Figure 3 Expression patterns of three biomarkers in large sections of HGDN and WDHCC. Expression patterns of ACY1 (A), SQSTM1 (B),
and GPC3 (C) examined by immunohistochemistry (×200) in HGDN and WDHCC validation set. Dotted line indicates the boundary between the
tumor (HGDN and WDHCC) and the non-tumor tissues. Insert shows high magnification image.
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WDHCC. This three-marker combination (−/+++/+++)
demonstrated the highest sensitivity and specificity in
terms of diagnostic value for diagnosing HCC, especially
early highly-differentiated HCC.
Tommaso et al. recently observed that the use of an
additional marker (clathrin heavy chain) improved the
performance (sensitivity) of the immunomarker panel
GPC3 + HSP70 + GS [30]. We aim to investigate the use
of additional markers, including those mentioned above,together with our previous proteomics results, to further
improve the sensitivity and specificity of the marker panels.
We demonstrated that ACY1 was expressed at low
levels in WDHCC, while SQSTM1 was expressed at high
levels in WDHCC tissues, compared with LGDN and
HGDN. ACY1 is a cytosolic, homodimeric, zinc-binding
enzyme that catalyzes the hydrolysis of acylated L-amino
acids to L-amino acids and acyl groups [31]. SQSTM1 is
an adapter protein that binds ubiquitin and may regulate






Figure 4 Kaplan-Meier curves of survival differences among HCC patients. OS and TTR for GPC3 expression in HCC tissue (A and B) and
serum AFP levels (C and D) were significantly different (log-rank test), while serum AFP combined with GPC3 (E and F) were highly significantly
different (log-rank test).
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Table 3 Univariate and multivariate analyses of factors associated with OS and TTR
OS TTR
Multivariate Multivariate
Factors Univariate p HR 95% Cl p Univariate p HR 95% Cl p
Sex: Male vs Female 0.870 NA 0.547 NA
Age: < 50 vs >50 0.241 NA 0.131 NA
HBsAg: positive vs negative 0.166 NA 0.178 NA
Cirrhosis: yes vs no 0.077 NA 0.135 NA
serum AFP (ng/ml): ≤ 20 vs > 20 0.005 NA 0.031 NA
Child-pugh: A vs B vs C 0.284 NA 0.225 NA
TNM: I vs II vs III-IV 0.000 1.534 1.262-1.864 0.000 0.000 1.496 1.243-1.801 0.000
tumor differentiation:
well vs moderate vs Poor 0.025 NS 0.236 NA
vascular invasion: yes vs no 0.002 NS 0.013 NA
ACY1: low vs high 0.930 NA 0.687 NA
SQSTM1: low vs high 0.438 NA 0.932 NA
GPC3: low vs high 0.001 NS 0.004 NS
AFP and GPC3 combination
A-/G high vs A-/G low or A+/ G high vs A+/G low 0.000 1.811 1.439-2.279 0.000 0.000 1.530 1.233-1.898 0.000
NOTE: Univariate analysis was calculated by the Kaplan–Meier method (the log-rank test). Multivariate analysis was done using the Cox multivariate proportional
hazard regression model with stepwise manner (forward, likelihood ratio). AFP, α-fetoprotein; A-, AFP negative; A+, AFP positive; G high, GPC3 high; G low,
GPC3 low; TTR, time to recurrence; OS, overall survival; NS, not significant; NA, not adopted; HR, hazard ratio; Cl, confidential interval.
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factor-α, nerve growth factor and interleukin-1 [32-34].
The present study demonstrated a gradual decrease in
ACY1 expression and a gradual increase in SQSTM1 and
GPC3 expression from LGDN to MDHCC, which were
confirmed by Spearman correlations and were in accor-
dance with the stepwise progression of hepatocarcin-
ogenesis. Although ACY1 and SQSTM1 showed no
prognostic values in this present study, they presented sig-
nificant diagnostic values and raised the sensitivity of
GPC3 for the detection of WDHCC.
GPC3 is a member of the glypican family of glycosyl-
phosphatidylinositol-anchored cell surface heparan sulfate
proteoglycans [35]. It is expressed in embryonic mesoder-
mal tissues and plays an important role in embryonal
growth [36,37]. In addition to HCC, GPC3 displays loss-of-
function mutations in Simpson-Golabi-Behmel syndrome
[36,37], and changes in GPC3 expression levels have been
detected in lung squamous cell carcinomas [38]. In the
present study, TNM stage and serum AFP were indepen-
dent prognostic factors for OS and TTR, in agreement
with previous reports [24,39,40]. Kaplan-Meier and multi-
variate survival analyses revealed that lower GPC3 ex-
pression was significantly linked to both poor OS and
increased risk of recurrence after surgical resection in
HCC patients. However, apart from studies on GPC3 stain-
ing in HCC tissues, few studies have reported any associ-
ation between high GPC3 expression and poor outcome inHCC patients [16-19]. This discrepancy might be partly re-
lated to the following factors. The above studies were based
on relatively small sample sizes (n = 61, 86, 107 and 185,
respectively), and the use of different GPC3 scoring sys-
tems may lead to contradictory results for predicting long-
term prognoses [18]. There may also have been differences
between studies in terms of factors such as antibody
sources and maximum follow-up time (Additional file 1:
Table S5). In addition, age, HBsAg, serum AFP, TNM, and
tumor differentiation differed significantly between GPC3-
low and GPC3-high patients (Additional file 1: Table S6),
and these results were similar to those from previous re-
ports [16-18]. To the best of our knowledge, the present
study evaluated GPC3 prognostic values using the largest
sample size (n = 500) with the longest follow-up time (up
to 12 years).
To date, few and limited data have been reported re-
garding the use of both serological and immunohisto-
chemical biomarkers to predict postoperative prognosis
in patients with HCC. As shown by Kaplan-Meier ana-
lysis, although either serum AFP or GPC3 staining alone
had prognostic values, OS and TTR were lower in pa-
tients with both positive serum AFP and low GPC3
expression. In addition, TNM staging and serum AFP
combined with GPC3 staining were adopted from Cox
multivariate regression analyses, indicating that TNM and
serum AFP/GPC3 staining may be a promising prognostic
parameter in HCC patients undergoing surgical resection.
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In conclusion, the present study constructed a molecular
model using logistic regression analysis for distinguish-
ing between WDHCC and HGDN. The combination of
ACY1 + SQSTM1 +GPC3 showed higher sensitivity and
specificity than other reported panels, and we suggest
that this combination represents a valuable differential
diagnostic model in hepatic immunopathology. In ad-
dition, serum AFP positivity and low GPC3 staining is
associated with poor prognosis, and can be a useful pre-
dictor to evaluate postoperative prognoses in patients
with HCC.
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